GSK Plans Phase 3 Trial for mRNA Flu Vaccine Candidate

MT newswire2026/09/01 07:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

03:35 AM EDT, 09/01/2026 (MT Newswires) -- GSK (GSK) plans to advance its mRNA seasonal influenza vaccine candidate to a phase 3 efficacy trial after the vaccine showed higher immune responses in a clinical study than licensed standard dose and high dose flu vaccines, the company said Tuesday. GSK said it plans to begin the phase 3 trial in September. The vaccine is designed to target both haemagglutinin and neuraminidase, two surface antigens involved in influenza virus binding and spread, it said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

As of this Tuesday (September 1), the yield on the 30-year U.S. Treasury reached 5.27%, exactly returning to the level before Besant announced the expansion on August 19. Meanwhile, the yield on the 10-year U.S. Treasury, which serves as a key benchmark for various loan rates, has risen by more than 10 basis points compared to that time, hovering around 4.8%.

智通财经•2026/09/01 23:11